X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs IPCA LABS - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA IPCA LABS CIPLA/
IPCA LABS
 
P/E (TTM) x 44.6 45.0 99.0% View Chart
P/BV x 3.8 3.5 110.6% View Chart
Dividend Yield % 0.3 0.1 225.8%  

Financials

 CIPLA   IPCA LABS
EQUITY SHARE DATA
    CIPLA
Mar-17
IPCA LABS
Mar-17
CIPLA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs622643 96.7%   
Low Rs458503 91.1%   
Sales per share (Unadj.) Rs181.9254.4 71.5%  
Earnings per share (Unadj.) Rs12.916.1 80.1%  
Cash flow per share (Unadj.) Rs29.329.8 98.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.40.2 212.1%  
Book value per share (Unadj.) Rs155.7194.6 80.0%  
Shares outstanding (eoy) m804.51126.20 637.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.3 131.9%   
Avg P/E ratio x42.035.7 117.7%  
P/CF ratio (eoy) x18.419.2 95.8%  
Price / Book Value ratio x3.52.9 117.8%  
Dividend payout %15.56.2 249.7%   
Avg Mkt Cap Rs m434,51672,300 601.0%   
No. of employees `00023.013.3 173.2%   
Total wages/salary Rs m26,3386,960 378.4%   
Avg. sales/employee Rs Th6,349.12,413.5 263.1%   
Avg. wages/employee Rs Th1,143.0523.2 218.5%   
Avg. net profit/employee Rs Th449.3152.4 294.8%   
INCOME DATA
Net Sales Rs m146,30232,106 455.7%  
Other income Rs m2,287226 1,013.2%   
Total revenues Rs m148,58932,332 459.6%   
Gross profit Rs m24,7584,448 556.6%  
Depreciation Rs m13,2291,730 764.9%   
Interest Rs m1,594241 661.9%   
Profit before tax Rs m12,2222,703 452.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798675 266.2%   
Profit after tax Rs m10,3542,028 510.6%  
Gross profit margin %16.913.9 122.2%  
Effective tax rate %14.725.0 58.9%   
Net profit margin %7.16.3 112.0%  
BALANCE SHEET DATA
Current assets Rs m87,37017,340 503.9%   
Current liabilities Rs m33,0819,559 346.1%   
Net working cap to sales %37.124.2 153.1%  
Current ratio x2.61.8 145.6%  
Inventory Days Days87100 86.7%  
Debtors Days Days6257 109.6%  
Net fixed assets Rs m111,56720,779 536.9%   
Share capital Rs m1,609252 637.5%   
"Free" reserves Rs m123,64524,499 504.7%   
Net worth Rs m125,25424,553 510.1%   
Long term debt Rs m36,4543,517 1,036.4%   
Total assets Rs m209,53239,595 529.2%  
Interest coverage x8.712.2 70.9%   
Debt to equity ratio x0.30.1 203.2%  
Sales to assets ratio x0.70.8 86.1%   
Return on assets %5.75.7 99.5%  
Return on equity %8.38.3 100.1%  
Return on capital %8.510.5 81.0%  
Exports to sales %34.248.6 70.3%   
Imports to sales %8.314.2 58.6%   
Exports (fob) Rs m50,05015,617 320.5%   
Imports (cif) Rs m12,2034,571 267.0%   
Fx inflow Rs m51,06615,617 327.0%   
Fx outflow Rs m17,6785,828 303.3%   
Net fx Rs m33,3889,790 341.1%   
CASH FLOW
From Operations Rs m23,8242,764 861.9%  
From Investments Rs m-13,127-1,432 916.8%  
From Financial Activity Rs m-13,239-1,591 831.9%  
Net Cashflow Rs m-2,478-259 957.5%  

Share Holding

Indian Promoters % 16.0 45.9 34.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.4 107.0%  
FIIs % 23.7 25.3 93.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.4 150.6%  
Shareholders   161,166 36,892 436.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ALEMBIC LTD  SUN PHARMA  SANOFI INDIA  FDC LTD.  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS